Orion Oyj B
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more
Orion Oyj B - Asset Resilience Ratio
Orion Oyj B (ORNBV) has an Asset Resilience Ratio of 11.16% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2022)
This chart shows how Orion Oyj B's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Orion Oyj B's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €183.60 Million | 11.16% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €183.60 Million | 11.16% |
Asset Resilience Insights
- Moderate Liquidity: Orion Oyj B has 11.16% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Orion Oyj B Industry Peers by Asset Resilience Ratio
Compare Orion Oyj B's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367 |
Drug Manufacturers - General | 32.14% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
Guangdong Jiaying Pharmaceutical Co Ltd
SHE:002198 |
Drug Manufacturers - General | 0.00% |
|
PharmGen Science Inc
KO:004720 |
Drug Manufacturers - General | 0.16% |
Annual Asset Resilience Ratio for Orion Oyj B (2000–2022)
The table below shows the annual Asset Resilience Ratio data for Orion Oyj B.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | -0.07% | €-1.00 Million | €1.50 Billion | +1.32pp |
| 2021-12-31 | -1.38% | €-15.40 Million | €1.11 Billion | -1.34pp |
| 2020-12-31 | -0.04% | €-500.00K | €1.12 Billion | -3.52pp |
| 2019-12-31 | 3.48% | €36.00 Million | €1.04 Billion | -0.80pp |
| 2018-12-31 | 4.27% | €49.00 Million | €1.15 Billion | +9.66pp |
| 2017-12-31 | -5.39% | €-56.90 Million | €1.06 Billion | -8.31pp |
| 2016-12-31 | 2.92% | €31.00 Million | €1.06 Billion | +5.64pp |
| 2015-12-31 | -2.72% | €-28.50 Million | €1.05 Billion | -10.01pp |
| 2014-12-31 | 7.29% | €73.00 Million | €1.00 Billion | +10.13pp |
| 2013-12-31 | -2.84% | €-27.80 Million | €979.00 Million | +2.19pp |
| 2011-12-31 | -5.03% | €-39.20 Million | €779.10 Million | -15.45pp |
| 2010-12-31 | 10.42% | €77.70 Million | €745.80 Million | -5.74pp |
| 2006-12-31 | 16.15% | €95.00 Million | €588.10 Million | +9.01pp |
| 2004-12-31 | 7.14% | €81.10 Million | €1.14 Billion | -2.05pp |
| 2003-12-31 | 9.20% | €112.80 Million | €1.23 Billion | -1.59pp |
| 2002-12-31 | 10.79% | €152.10 Million | €1.41 Billion | -9.19pp |
| 2001-12-31 | 19.98% | €189.50 Million | €948.50 Million | -2.31pp |
| 2000-12-31 | 22.29% | €203.90 Million | €914.60 Million | -- |